| Aug 7 |
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
|
| Aug 6 |
Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms
|
| Aug 1 |
Context Therapeutics appoints Claudio Ullmann as chief medical officer
|
| Aug 1 |
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
|
| Jul 10 |
Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline
|
| Jul 10 |
Context Therapeutics acquires phase 1-ready T cell engager CT-95
|
| Jul 10 |
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
|
| Jun 12 |
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
|
| May 20 |
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
|
